Kidney involvement in COVID-19 and rationale for extracorporeal therapies

Ministero della Salute. Covid-19. Situazione in Italia. Ministero della Salute. Salute.gov http://www.salute.gov.it/imgs/C_17_pagineAree_5351_30_file.pdf (2020).

Guan, W.-j. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2002032 (2020).

Neelapu, S. S. et al. Chimeric antigen receptor T cell therapy — assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47–62 (2018).

Wu, C. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. https://doi.org/10.1001/jamainternmed.2020.0994 (2020).

Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).

Girardot, T., Schneider, A. & Rimmelé, T. Blood purification techniques for sepsis and septic AKI. Semin. Nephrol. 39, 505–514 (2019).

Ronco, C., Reis, T. & De Rosa, S. Coronavirus epidemic and extracorporeal therapies in intensive care: si vis pacem para bellum. Blood Purif. https://doi.org/10.1159/000507039 (2020).

Panitchote, A. et al. Factors associated with acute kidney injury in acute respiratory distress syndrome. Ann. Intensive Care 9, 74 (2019).

Husain-Syed, F., Slutsky, A. S. & Ronco, C. Lung-kidney cross-talk in the critically ill patient. Am. J. Respir. Crit. Care Med. 194, 402–414 (2016).

Klein, D. J. et al. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 44, 2205–2212 (2018).